scispace - formally typeset
Search or ask a question
Author

Paul Calès

Bio: Paul Calès is an academic researcher from University of Angers. The author has contributed to research in topics: Cirrhosis & Portal hypertension. The author has an hindex of 61, co-authored 353 publications receiving 14123 citations. Previous affiliations of Paul Calès include University of Bordeaux & National Autonomous University of Mexico.


Papers
More filters
Journal ArticleDOI
TL;DR: Gut microbiota analysis adds information to classical predictors of NAFLD severity and suggests novel metabolic targets for pre‐/probiotics therapies, and identifies Bacteroides as independently associated with NASH and Ruminococcus with significant fibrosis.

896 citations

Journal ArticleDOI
TL;DR: Whereas the Fibrometer has a high diagnostic accuracy for clinically significant fibrosis, blood tests for the area of liver fibrosis provide a quantitative estimation of the amount of fibrosis which is especially useful in cirrhosis.

540 citations

Journal ArticleDOI
TL;DR: The level of experience (specialization, duration, and location of practice) has more influence on agreement than the characteristics of the specimen (length, fibrosis class number, miscellaneous factors).

504 citations

Journal ArticleDOI
TL;DR: The usual definition for LSE reliability is not relevant, and three reliability categories are defined: very reliable, reliable, and poorly reliable LSE.

477 citations

Journal ArticleDOI
TL;DR: In this paper, the authors analyzed data on individual patients from four randomized, controlled trials to assess the efficacy of the beta-adrenergic-antagonist drug therapy for the prevention of initial episodes of gastrointestinal bleeding.
Abstract: Background. The value of beta-adrenergic—antagonist drug therapy for the prevention of initial episodes of gastrointestinal bleeding in patients with cirrhosis and esophageal varices is uncertain, both positive and negative study results having been reported. Methods. In this study, we analyzed data on individual patients from four randomized, controlled trials to assess the efficacy of this treatment. Of the 589 patients studied, 286 received a beta-adrenergic—antagonist drug (propranolol in 203 and nadolol in 83) and 303 received placebo. Results. After two years, the mean (±SE) percentage of patients who had had no upper gastrointestinal bleeding was 78±3 percent in the beta-adrenergic—antagonist treatment group and 65±3 percent in the control group (P = 0.002). The percentage of patients without fatal bleeding was 90±2 percent in the treatment group and 82±3 percent in the control group (P = 0.01). The percentage of patients surviving after two years was 71 ±3 percent in the treatment group a...

419 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

7,851 citations

Journal ArticleDOI
TL;DR: The Sydney System for the classification of gastritis emphasized the importance of combining topographical, morphological, and etiological information into a schema that would help to generate reproducible and clinically useful diagnoses as discussed by the authors.
Abstract: The Sydney System for the classification of gastritis emphasized the importance of combining topographical, morphological, and etiological information into a schema that would help to generate reproducible and clinically useful diagnoses. To reappraise the Sydney System 4 years after its introduction, a group of gastrointestinal pathologists from various parts of the world met in Houston, Texas, in September 1994. The aims of the workshop were (a) to establish an agreed terminology of gastritis; (b) to identify, define, and attempt to resolve some of the problems associated with the Sydney System. This article introduces the Sydney System as it was revised at the Houston Gastritis Workshop and represents the consensus of the participants. Overall, the principles and grading of the Sydney System were only slightly modified, the grading being aided by the provision of a visual analogue scale. The terminology of the final classification has been improved to emphasize the distinction between the atrophic and nonatrophic stomach; the names used for each entity were selected because they are generally acceptable to both pathologists and gastroenterologists. In addition to the main categories and atrophic and nonatrophic gastritis, the special or distinctive forms are described and their respective diagnostic criteria are provided. The article includes practical guidelines for optimal biopsy sampling of the stomach, for the use of the visual analogue scales for grading the histopathologic features, and for the formulation of a comprehensive standardized diagnosis. A glossary of gastritis-related terms as used in this article is provided.

4,511 citations

Journal ArticleDOI
TL;DR: A simple algorithm that generates a single activity score based on basic pathological features in chronic hepatitis C is proposed and tested, showing its accuracy is as high as that obtained using a statistical approach.

3,567 citations

01 Jan 2012
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Abstract: EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies recommended for patients with this type of cancer. This is the first European joint effort by the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) to provide common guidelines for the management of hepatocellular carcinoma. These guidelines update the recommendations reported by the EASL panel of experts in HCC published in 2001 [1]. Several clinical and scientific advances have occurred during the past decade and, thus, a modern version of the document is urgently needed. The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data. Users of these guidelines should be aware that the recommendations are intended to guide clinical practice in circumstances where all possible resources and therapies are available. Thus, they should adapt the recommendations to their local regulations and/or team capacities, infrastructure, and cost– benefit strategies. Finally, this document sets out some recommendations that should be instrumental in advancing the research and knowledge of this disease and ultimately contribute to improve patient care. The EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data (the classification of evidence is adapted from National Cancer Institute [2]) (Table 1A) and the strength of recommendations following previously reported systems (GRADE systems) (Table 1B).

2,594 citations

Journal ArticleDOI
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.

2,491 citations